Entecavir — Discount Pricing

Other medications in Infections

• Ertapenem
• Erythromycin
• Ethambutol
• Famciclovir
• Fluconazole
• Foscarnet
• Fosfomycin
• Ganciclovir

About Entecavir

Entecavir is a vital antiviral medication prescribed to manage chronic Hepatitis B virus (HBV) infection, a serious condition affecting the liver. For those needing long-term treatment, the cost can be a significant concern. TheDrugClub is dedicated to making essential medications like entecavir more accessible and affordable for our members, helping you focus on your health, not just the price tag.

Entecavir: A Key Treatment for Chronic Hepatitis B

Entecavir is an oral antiviral medication primarily used to treat chronic Hepatitis B virus (HBV) infection in adults and children aged two years and older. Chronic HBV is a persistent viral infection that can lead to severe liver damage, including cirrhosis, liver failure, and liver cancer, if left untreated. By effectively suppressing the virus, entecavir helps to reduce the risk of these life-threatening complications and improve overall liver health.

How Entecavir Works to Combat HBV

As a nucleoside analogue reverse transcriptase inhibitor (NRTI), entecavir works by targeting a specific enzyme within the Hepatitis B virus: HBV reverse transcriptase. This enzyme is crucial for the virus to replicate and multiply within the body. By blocking its action, entecavir significantly reduces the amount of HBV in the blood, thereby decreasing viral load and minimizing damage to the liver. It's important to understand that while entecavir is highly effective in managing the infection and preventing progression, it is not a cure for Hepatitis B. Patients typically require long-term, often lifelong, treatment to keep the virus under control.

Understanding the Cost of Entecavir

Antiviral medications like entecavir, especially for chronic conditions, can represent a substantial financial commitment. The typical cost for a 30-day supply of generic entecavir can vary widely, often ranging from hundreds of dollars, depending on the dosage, pharmacy, and your location. The brand-name version, Baraclude, is generally more expensive

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Entecavir is approved for (FDA label)

Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)

Source: Read the full FDA label on DailyMed. Label effective date: July 7, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Entecavir (FDA label)

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR TABLETS, for oral use Initial U.S. Approval: 2005 WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS COINFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection that is not being treated.

Source: FDA prescribing information (DailyMed). Set ID: 73dea2a4-a596-477f-b66d-5a80dd019837. SPL document ID: 5611fb30-bf3a-7dae-e063-6294a90a08ed. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Entecavir (FDA label)

Entecavir Tablets, USP, 0.5 mg, are supplied as a white to off-white, round film coated tablets, debossed with “Y13” on one side. Entecavir Tablets, USP, 1 mg, are supplied as a white to off-white, round film coated tablets, debossed with “Y14” on one side. Tablets: 0.5 mg and 1 mg (3 , 16)

Source: FDA prescribing information (DailyMed). Set ID: 73dea2a4-a596-477f-b66d-5a80dd019837. SPL document ID: 5611fb30-bf3a-7dae-e063-6294a90a08ed. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Entecavir (FDA label)

The following adverse reactions are discussed in other sections of the labeling: Exacerbations of hepatitis after discontinuation of treatment [see Boxed Warning , Warnings and Precautions (5.1) ] . Lactic acidosis and severe hepatomegaly with steatosis [see Boxed Warning , Warnings and Precautions (5.3) ] . In adults, the most common adverse reactions (≥ 3%, all severity grades) are headache, fatigue, dizziness, and nausea.

Source: FDA prescribing information (DailyMed). Set ID: 73dea2a4-a596-477f-b66d-5a80dd019837. SPL document ID: 5611fb30-bf3a-7dae-e063-6294a90a08ed. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Entecavir (FDA label)

Severe acute exacerbations of hepatitis B virus infection after discontinuation: Monitor hepatic function closely for at least several months. (5.1 , 6.1) Co-infection with HIV: Entecavir is not recommended unless the patient is also receiving HAART. (5.2) Lactic acidosis and severe hepatomegaly with steatosis: If suspected, treatment should be suspended. (5.3) 5.1 Severe Acute Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir [see Adverse Reactions (6.1) ] . Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted. 5.2 Patients Co-infected with HIV and HBV Entecavir has not been evaluated in HIV/HBV co-infected patients who were not simultaneously receiving effective HIV treatment.

Source: FDA prescribing information (DailyMed). Set ID: 73dea2a4-a596-477f-b66d-5a80dd019837. SPL document ID: 5611fb30-bf3a-7dae-e063-6294a90a08ed. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Entecavir (FDA label)

Since entecavir is primarily eliminated by the kidneys [see Clinical Pharmacology (12.3) ] , coadministration of entecavir with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug. Coadministration of entecavir with lamivudine, adefovir dipivoxil, or tenofovir disoproxil fumarate did not result in significant drug interactions. The effects of coadministration of entecavir with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when entecavir is coadministered with such drugs.

Source: FDA prescribing information (DailyMed). Set ID: 73dea2a4-a596-477f-b66d-5a80dd019837. SPL document ID: 5611fb30-bf3a-7dae-e063-6294a90a08ed. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.